Determinants of Clinical Remission in Dupilumab-Treated Severe Eosinophilic Asthma: A Real-World Retrospective Study

<b>Background</b>: Dupilumab, a monoclonal antibody targeting the IL-4/IL-13 receptor, has shown significant efficacy in improving asthma control and reducing exacerbations in patients with severe eosinophilic asthma. However, there is a lack of knowledge about real-world data on clinical remission...

Descrición completa

Detalles Bibliográficos

Principais autores:	Matteo Bonato, Elisabetta Favero, Francesca Savoia, Matteo Drigo, Simone Rizzato, Enrico Orzes, Gianenrico Senna, Micaela Romagnoli
Formato:	Artigo
Idioma:	Inglês
Publicado:	MDPI AG 2025-09-01
Series:	Biomedicines
Assuntos:	CRSwNP GERD obesity hypertension bronchiectasis biologics
Acceso en liña:	https://www.mdpi.com/2227-9059/13/10/2404
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!